2 863 169 libros electrónicos en 110 idiomas
¿No le conviene? No hay problema. Puede devolverlo en un plazo de 30 días
No se equivocará con un vale de regalo. El destinatario puede elegir cualquier producto de nuestra oferta.
Política de devolución de 30 días
Lung cancer is the leading cause of all cancer related deaths worldwide. The 5-year survival rate ranges from 80% in early stages to less than 5% in advanced disease. Non-small cell lung carcinoma (NSCLC) accounts for 80% of all lung malignancies, 40% of which are adenocarcinomas representing one of the most common lung cancer subtypes. Currently, prognosis is mostly determined based on the extension of disease at diagnosis. Thereby it has become evident that predicted and real outcomes can vary significantly, even for patients with the same stage of disease. Thus, novel biomarkers that refine prognosis with a reliable clinical significance are clearly needed. Therefore we aimed to implement an activity-based proteomics platform representing a powerful tool in the search for novel disease biomarkers.
¡Hola! Soy Libroamiko, tu asesor de libros.
¿Cómo puedo ayudarte?